Last reviewed · How we verify
Ervebo® booster
Ervebo booster is a recombinant vesicular stomatitis virus (VSV)-based vaccine booster designed to enhance and sustain immune responses against Ebola virus.
Ervebo booster is a recombinant vesicular stomatitis virus (VSV)-based vaccine booster designed to enhance and sustain immune responses against Ebola virus. Used for Ebola virus disease prevention (booster vaccination in previously primed individuals).
At a glance
| Generic name | Ervebo® booster |
|---|---|
| Sponsor | Institute of Tropical Medicine, Belgium |
| Drug class | Live attenuated viral vaccine |
| Target | Ebola virus glycoprotein (EBOV GP) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ervebo is a live attenuated VSV vector vaccine expressing the Ebola virus glycoprotein, which primes the immune system. The booster dose is administered to enhance and prolong protective immunity after an initial Ervebo vaccination series. This heterologous prime-boost strategy leverages the VSV platform to generate robust cellular and humoral immune responses against Ebola.
Approved indications
- Ebola virus disease prevention (booster vaccination in previously primed individuals)
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure (PHASE3)
- Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |